25.91
1.69%
-0.415
Arcturus Therapeutics Holdings Inc stock is currently priced at $25.91, with a 24-hour trading volume of 237.11K.
It has seen a -1.69% decreased in the last 24 hours and a -23.36% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $26.68 pivot point. If it approaches the $25.49 support level, significant changes may occur.
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Arcturus Therapeutics Holdings Inc (ARCT) Revenue 2024
ARCT reported a revenue (TTM) of $157.75 million for the quarter ending December 31, 2023, a -23.33% decline year-over-year.
Arcturus Therapeutics Holdings Inc (ARCT) Net Income 2024
ARCT net income (TTM) was -$29.73 million for the quarter ending December 31, 2023, a -417.95% decrease year-over-year.
Arcturus Therapeutics Holdings Inc (ARCT) Cash Flow 2024
ARCT recorded a free cash flow (TTM) of -$21.00 million for the quarter ending December 31, 2023, a -186.54% decrease year-over-year.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings per Share 2024
ARCT earnings per share (TTM) was -$1.16 for the quarter ending December 31, 2023, a -441.18% decline year-over-year.
Arcturus Therapeutics Holdings Inc Stock (ARCT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Chivukula Pad | Chief Scientific Officer & COO |
Mar 19 '24 |
Sale |
35.01 |
8,565 |
299,839 |
490,883 |
Chivukula Pad | Chief Scientific Officer & COO |
Nov 01 '23 |
Sale |
18.72 |
5,000 |
93,602 |
499,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Oct 02 '23 |
Sale |
25.61 |
5,000 |
128,062 |
504,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Sep 01 '23 |
Sale |
31.45 |
5,000 |
157,264 |
509,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Aug 01 '23 |
Sale |
34.91 |
5,000 |
174,550 |
514,448 |
Kummerfeld Keith C | See Remarks |
Jul 14 '23 |
Option Exercise |
8.96 |
6,968 |
62,408 |
7,918 |
Chivukula Pad | Chief Scientific Officer & COO |
Jul 14 '23 |
Sale |
35.01 |
25,000 |
875,250 |
519,448 |
Kummerfeld Keith C | See Remarks |
Jul 14 '23 |
Sale |
35.00 |
6,968 |
243,880 |
950 |
Chivukula Pad | Chief Scientific Officer & COO |
Jul 03 '23 |
Sale |
28.75 |
5,000 |
143,750 |
544,448 |
Chivukula Pad | Chief Scientific Officer & COO |
Jun 01 '23 |
Sale |
27.16 |
5,000 |
135,800 |
549,448 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Benzinga
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Zacks Investment Research
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Benzinga
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
Zacks Investment Research
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):